Abstract Anti-inflammatory activities of statins in atherosclerosis have been well documented by both basic research and clinical studies. Statins have been introduced in the 1980s as 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to block cholesterol synthesis and lower cholesterol serum levels. In the last three decades, statins have been shown to possess several antiinflammatory and antioxidant activities resulting in the beneficial reduction of atherosclerotic processes and cardiovascular risk in both humans and animal models. Inflammatory intracellular pathways involving kinase phosphorylation and protein prenylation are modulated by statins. The same intracellular mechanisms might also cause statin-induced myotoxicity. In the present review, we will update evidence on statin-mediated regulation of inflammatory pathways in atherogenesis.
Introduction
Cardiovascular diseases are the leading cause of death and disability in the adult population of developed and developing countries [1] [2] [3] . In the majority of patients, clinical cardiovascular disease is the final step of the inflammatory state characterizing atheroprogression. Stable advanced atherosclerotic plaques mainly induce chronic arterial lumen stenosis and ischemia in peripheral tissues. This condition causes chronic organ remodeling and alters their functions. In the heart, chronic hypoxia can induce congestive heart failure (CHF). On the other hand, unstable plaques frequently progress to rupture with the consequent exposure to the blood lumen of intraplaque prothrombotic material. In that case, thrombus causes the sudden complete occlusion of the arterial lumen, and peripheral tissues are exposed to acute ischemia. If collateral arteries are not present and acute ischemia is prolonged, tissue necrosis can occur with dramatic consequences in the heart and brain. Several cardiovascular risk factors have been associated with CVD. More than 50 years ago, this concept was introduced by the Framingham Heart Study, with the identification of major coronary heart disease (CHD) risk factors, such as hypertension, hyperlipidemia, smoking, and diabetes [4] . However, although highly sensitive, these traditional factors showed a very low specificity [5] [6] [7] . Therefore, inflammatory soluble mediators, which have been shown to play a central role in all phases of atherosclerosis, have been investigated [8] [9] [10] with some preliminary encouraging results. In particular, the American Heart Association (AHA/CDC) has recently suggested that the high sensitivity dosage of the acute phase reactant C-reactive protein (CRP) might be useful when physicians are undecided about indications of a more intensive treatment for patients who are considered at intermediate cardiovascular risk [11, 12] . At present, the most promising therapeutic strategies to reduce cardiovascular diseases are represented by the selective blockade of both "classical" and new emerging factors promoting atherogenesis. Statins (3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors) should be considered as anti-atherosclerotic drugs capable of modulating different factors. Basic research and clinical studies have shown that statins lower LDL cholesterol levels and inhibit atherosclerotic inflammatory processes. Little is known on the possible statin-mediated molecular mechanisms to reduce cardiovascular risk. In the present review, we will focus on selective anti-inflammatory activities of members of statin family and the statin-mediated modulation of intracellular pathways in both immune and vascular cells, which play a crucial role in atherosclerosis.
Statins in cardiovascular diseases
The first identification of a fungal metabolite (compactin) blocking cholesterol synthesis has been performed in 1971 by Endo and coworkers [13] . In 1976, the "Compactin Development Project" composed by several experts started. Starting from 1978, a new statin (called lovastatin) has been discovered and developed. In 1980s, statins have been shown to lower LDL cholesterol levels in patients with hypercholesterolemia [14] [15] [16] [17] [18] . These first impressive results induced the US Food and Drug Administration to approve the commercial us of statins in 1986 [19] . After lovastatin, three generations of statins have been commercially introduced: pravastatin and fluvastatin (first generation), atorvastatin and simvastatin (second generation), and rosuvastatin and pitavastatin (third generation). Cerivastatin was also approved for the marketplace but was eventually discontinued for its myotoxic effects [13] . Statins have been tested in primary prevention for acute cardiovascular events in both high cardiovascular risk patients (diabetes, hypertension, and dyslipidemia) and subjects with low or no CVD risk [20] [21] [22] [23] [24] [25] . For instance, aggressive treatment of diabetic subjects with statins has been shown to reduce coronary events and stroke [21] [22] [23] . This was also observed in diabetic patients with dyslipidemia [26] . The principal primary prevention study in hypertensive patients (AngloScandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA)) showed that atorvastatin reduces the relative risk of primary CHD [27] . On the other hand, The Intervention Trial Evaluating Rosuvastatin (JUPITER, a large multinational, long-term, double blind, and randomized clinical trial) showed that treatment with rosuvastatin significantly reduces the incidence of major cardiovascular events in healthy subjects without hyperlipemia but with elevated high-sensitivity CRP levels [28] . Statins have been also investigated in secondary prevention of cardiovascular diseases. Results have been reported in patients with stable coronary artery disease, acute coronary syndrome, stroke, or transient ischemic attack [29] [30] [31] [32] [33] [34] [35] [36] . The Scandinavian Simvastatin Survival Study (4S), performed in patients with angina pectoris or previous myocardial infarction and high-serum cholesterol levels, demonstrated that longterm treatment with simvastatin improves survival and decreases cardiovascular events [37] . The Heart Protection Study (HPS; a primary and secondary prevention study) showed that simvastatin significantly reduced cardiovascular mortality and vascular acute events in 20,000 patients with coronary or peripheral vascular disease without hyperlipidemia [38] . The Greek Atorvastatin and Coronary Heart Disease Evaluation, Treating to New Targets (TNT), Aggressive Lipid-Lowering Initiation Abates New Cardiac Events, and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering (IDEAL) studies confirmed a significant decrease of acute cardiovascular events in patients with stable CHD [39, 40] . The Pravastatin or Atorvastatin Evaluation and Infection Therapy, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL), and IDEAL-Acute Coronary Syndromes studies demonstrated the benefits of high-dose-dosage atorvastatin therapy in patients with acute coronary syndromes [40] . In patients with heart failure, the efficacy of statins is still a matter of dispute [41, 42] . In the GISSI-HF trial, rosuvastatin did not reduce death or admission to hospital for cardiovascular reasons in patients with chronic heart failure [42] . The CORONA study partially confirmed these results showing only a reduction of the number of cardiovascular hospitalizations [43] . Statins also improved survival and cardiovascular events in patients after heart transplantation or percutaneous coronary interventions [41] promoting coronary collateral circulation, a modest antihypertensive effect and improving glucose metabolism and insulin sensitivity [44] [45] [46] . Although few controversies remain, these clinical studies indicate that: (1) statins should be considered as very promising anti-atherosclerotic drugs (also independently on lowering cholesterol) for secondary prevention in all patients and for primary prevention in high risk individuals (Fig. 1) . (2) In persons without traditional cardiovascular risk factors, but with elevated hs-CRP levels, the use of statins might be indicated in the near future. (3) The marked cardiovascular risk reduction might be also related to the direct anti-inflammatory and pleiotropic properties of statins [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] . The National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III recommended the use of statins for the secondary prevention of cardiovascular diseases as the first-line choice drug for lowering LDL-cholesterol in the high-risk patients [60] . This group includes individuals with established coronary heart disease and diabetes mellitus or with a Framingham 10-year CHD risk greater than 20%. For primary prevention, the NCEP ATP III recommended to treat individuals with metabolic syndrome and diabetic patients with moderate cardiovascular risk (Framingham 10-year CHD risk of 10-20%) [61] . Treatment with any of the statin family has been associated with transaminase elevations in comparison to placebo [62] . Despite the low frequency (1-2%) of raised asparatate or alanine aminotransferase, these adverse effects are completely reversible and almost never progress to hepatitis or liver failure [63] . A very low risk of neuropathy and gastrointestinal discomfort has been also reported. However, the main risk of statin treatment derives from myotoxicity which ranges from myalgias, creatine kinase elevation to the more serious rhabdomyolysis. This adverse effect has been reported in 1-7% of patients under statin therapy [64] . Itagaki and coworkers recently suggested that myotoxicity could be induced by the same mechanisms governing statin beneficial antiinflammatory activities. In particular, RhoA dysfunction due to loss of lipid modification with the mevalonate product geranylgeranylpyrophosphate (GGPP) has been observed in statin-induced skeletal muscle toxicity [65] . Further investigations are needed to better clarify the role of intracellular signaling pathways in myotoxicity. Despite these few adverse effects, statins are generally well tolerated. Both second and third generations of statins have been shown to reduce LDL cholesterol more effectively than first generation without increasing toxicity [66] . In the following, we will discuss on the selective immunomodulatory properties of different statins (Table 1) [67].
Lovastatin
Together with pravastatin and fluvastatin, lovastatin is included in the first generation of statins. Lovastatin represents the drug with the lowest potency and is necessary to use high doses to observe a significant reduction of LDL cholesterol levels [68] . However, lovastatin (together with simvastatin and pravastatin) is less expensive, and it is available in generic formulation. Clinical studies have also confirmed the efficacy of lovastatin in both primary and secondary prevention of cardiovascular diseases. The AFCAPS/TexCAPS study showed that daily treatment with 20-40 mg lovastatin-reduced incidence of acute major cardiac events in comparison with placebo. The study was performed in a middle-aged or elderly population (n=6,605) without symptomatic cardiovascular disease [69] . The beneficial effects of lovastatin were confirmed by the ACAPS study that enrolled 919 subjects asymptomatic for clinical cardiovascular disease but with evidence of early carotid atherosclerosis [70] . On the other hand, secondary prevention studies showed that 2-2.5-year therapy with lovastatin-reduced progression of atherosclerosis in dyslipidemic patients with CHD [71] [72] [73] . Lovastatin has been also [157] . Ator-vastatin has been also shown to directly induce neuroprotection. It reduced neurological deficit by increasing synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury [158] . In the same rat model, atorvastatin also reduced intravascular thrombosis and increased cerebral microvascular integrity [159] . Furthermore, atorvastatin inhibited perihematomal cell death in adult rats after experimental intracerebral hemorrhage [160] . As other statins, atorvastatin directly antagonized inflammatory processes in human brain endothelial cells [161] . The direct neuro and endothelial protective activities of atorvastatin have been shown to reduce stroke consequences in stroke-prone spontaneously hypertensive rats and in a rat model of embolic stroke [162, 163] . These studies strongly suggest that atorvastatin could be a very promising drug with potent anti-inflammatory activities in different diseases. The possible use of atorvastatin to inhibit atherosclerosis represents the best investigated field. Atorvastatin reduced in vitro and in vivo endothelial dysfunction and inflammatory processes in atherogenesis. As previously indicated for simvastatin, atorvastatin protects endothelium through the increase of endothelial cell progenitor proliferation and mobilization and the induction of vessel wall stabilizing mediators and growth factors in endothelial cells [111, [164] [165] [166] . Atorvastatin has been shown to inhibit cytokine-inducible nitric oxide synthase, CD40, CD40L, chemokine, and thrombospondin-1 expression in endothelial cells [167] [168] [169] [170] [171] [172] . Atorvastatin also regulates immune cell functions and the release of inflammatory mediators such as CRP. We have recently shown that atorvastatin inhibit CRP production on IL6-treated human hepatocytes [173] . Furthermore, this drug reduces CRP or granulocyte macrophage-colony stimulating factor-mediated proinflammatory activities in human monocytes [137, 174] . Atorvastatin also interferes with T lymphocyte, B lymphocyte, or dendritic cell activation and differentiation [175] [176] [177] [178] [179] . Atorvastatin-mediated antiinflammatory effects have been observed also in clinical studies, investigating inflammatory cardiovascular risk markers in acute coronary syndromes, and coronary artery disease [180, 181] . Further investigations are needed to better assess the role of atorvastatin treatment in the reduction of inflammatory cardiovascular risk factors. Taken together, clinical and basic research studies suggest that high-dose atorvastatin treatments rather than low-dose could be considered as a promising approach to reduce cardiovascular disease.
Rosuvastatin
Rosuvastatin is a synthetic HMG-CoA reductase inhibitor noncompetitive with the cosubstrate nicotinamide-adnine dinucleotide phosphate [182] . Compared to other statins, rosuvastatin is the most effective to reduce total and LDL-cholesterol levels for mg/dose equivalent. As atorvastatin, rosuvastatin has been shown to additionally bind the enzyme complex not only at the HMG-CoA reductase site [183] . As pravastatin, it is significantly less lipophilic than other statins. Differently from other statins, rosuvastatin is metabolized mainly through CYP2C9 [183] . These pharmacologic and pharmacokinetic aspects support this drug as a very promising candidate to reduce myotoxicity and interaction with other drugs, and improve anti-inflammatory properties. Several clinical studies included in the global GALAXY program have been performed to assess rosuvastatin's clinical efficacy in atherogenic lipid profile, changes in atheroma volume, and cardiovascular morbidity and mortality in different subpopulations [184] . As described above, the recent JUPITER study is the first primary prevention study demostrating a benefit of statin therapy in individuals with elevated high-sensitivity C-reactive protein levels, but without hyperlipidemia [28] . In secondary prevention, rosuvastatin did not reduce mortality in patients with systolic heart failure and CAD but only the number of cardiovascular hospitalizations. Conversely, the ASTEROID trial demonstrated decrease of percent diameter stenosis and amelioration of minimum lumen diameter in coronary disease patients [185] . Although atherosclerotic lesion regression is not directly related to the reduction of future cardiovascular outcomes, the ASTEROID study strongly supports the possible use of rosuvastatin in secondary prevention. High concentrations of rosuvastatin (100 μM) suppressed monocytic cell adhesion and ICAM-1, MCP-1 IL-8, IL-6, and COX-2 expression on TNF-alpha-stimulated HUVEC [186] . Furthermore, although mechanisms have not been identified yet, rosuvastatin treatment protected mice from ischemic stroke [187] and rats from myocardial reperfusion injury [188] . Rosuvastatin also exerts favorable anti-atherosclerotic effects in several animal models [189] [190] [191] [192] . These studies suggest that rosuvastatin-mediated benefits are dependent of its antioxidant and anti-inflammatory activity on endothelial cells. A recent study (performed in a small number of patients (n=48)) further confirmed the endothelial protective properties of rosuvastatin showing that short-term treatment increases endothelial cell progenitor mobilization [193] .
The effects of statins on inflammatory intracellular signaling pathways
Statins have been introduced as HMG-CoA reductase inhibitors to lower LDL-cholesterol synthesis and serum levels (Fig. 2) . However, emerging evidence has shown that the "classical" cholesterol pathway could also modulate intracellular signaling pathways involving protein kinases in different cell types. Thus, statins could directly influence vascular and immune cells, hepatocyte, and adipocyte inflammatory functions through the activation of certain intracellular mediators or the inhibition of protein kinase phosphorylation of intracellular second messenger cascades (Fig. 3) . metabolism. Emerging evidence showed that AMPK might be crucial in vascular protection [194] . Statins directly activates AMPK in different cell types [194, 195] . In particular, statins have been shown to rapidly activate this protein kinase in vitro (cultured HUVEC) and in vivo (mouse aorta and myocardium). Such phosphorylation resulted in eNOS activation that could explain the direct beneficial effects of statins in cardiovascular diseases [196] . Interestingly, statin-mediated AMPK activation was dependent on the upstream activation of PKC-zeta as shown in endothelial cells and in vivo in mice [197] . AMPK-induced eNOS activation also increased endothelial cell progenitor differentiation in endothelial cells indicating a possible protective mechanism on endothelium mediated by statins [198] . On the other hand, the activation of phosphoinositide 3 kinase (PI3K)/Akt (protein kinase B) represents a critical step in inflammatory cell survival, locomotion in atherosclerosis, and cardiovascular disease [199] . Although, few studies (performed with lovastatin) suggested a possible inhibition of PI3K-Akt in endothelial cells [200] , there is a general consensus that statins induce cardiovascular protection through the activation of PI3K/ Akt pathway. Statin-mediated neuroprotection in animal models of traumatic brain injury and embolic stroke is dependent on PI3K/Akt pathway activation [163, 201, 202] . This pathway involves also the activation of NF-kB that suppresses caspase-3 and apoptosis cell death [203] . Neuronal nitric oxide synthase upregulation might represent the final effector of this protective pathway [204] . Statin-mediated myocardial protection has been also shown as dependent on PI3K/Akt activation pathway in both in vitro and in vivo models [205] [206] [207] . Atherogenesis is also regulated by PI3K/Akt pathway. Statins induce their activation on vascular and immune cells, thus, reducing atherosclerotic lesions in ApoE knockout mice [208] and endothelial dysfunction in type 2 diabetic mice [209] . Controversial results on statin-mediated MAPK phosphorylation have been showed. Statins induce antiinflammatory activities through both activation and inhibition of these kinases. The statin-induced activation of extracellular signal-regulated kinase (ERK) 1/2 has been observed mainly in immune cells [210, 211] . On the other hand, statins increase macrophage apoptosis through JNK activation [81].
Statin-mediated activation of intracellular pathways

Statin-mediated inhibition of intracellular pathways
As largely discussed, statins have been approved as HMG-CoA reductase inhibitors. The HMG-CoA/mevalonate pathway is essential for cellular metabolism and the formation of precursors of bile acids, lipoproteins and hormones, and nonsterol isoprenoids. These molecules regulate cell growth and differentiation, gene expression, protein glycosylation, and cytoskeletal assembly [212] . Thus, by influencing cholesterol synthesis, statins not only reduce circulating LDL-cholesterol levels but also induce important cellular modifications which could interfere with immune and thrombotic response. Furthermore, statin reduce mevalonate-derived molecules, such as farnesylpyrophosphate (FPP) and GGPP which are essential players in cell signaling, endocytotic/exocytotic transport, and cytoskeleton dynamics [213] . Immune cell functions (including chemotaxis, chemokine secretion, and oxidative metabolism) are regulated by the "classical" mevalonate pathway. Endothelial and smooth muscle cells require this pathway for their proinflammatory functions [213] . Therefore, anti-inflammatory properties of stains might be due to their "classical" pharmacologic properties. Small GTP-binding proteins, which include in the Ras, Rho, Rab, and Ran superfamily, are directly modulated by the mevalonate pathway. These proteins act as molecular "on-off" switches regulating actin cytoskeleton changes in cell adhesion, migration and contraction [214] . They regulate several downstream intracellular messengers, such as protein kinase N, p21-activated protein kinase, and the rho-associated kinases, which control not only cellular locomotion but also cell growth and apoptosis in both immune and vascular cells [215] . Recently, it has been shown that the effects of statins on atherosclerotic processes in the vessel wall and in the brain are partially due to the inhibition of the Rho pathway [216, 217] .
Conclusion
Due to their beneficial properties in cardiovascular diseases, statins are among the most widely prescribed medications in the world. Despite some differences between members of the statin family, all these drugs have been shown to reduce cardiovascular events in both primary and secondary prevention. The recent results of the JUPITER Study seem to indicate that statin treatment in CRP-elevated primary prevention markedly reduced cardiovascular events and total mortality. The safety of statins has been largely documented. Beside their well-known lipid lowering effects, statins also affect some immunomodulatory activities. These so called "pleiotropic" effects induce a decrease in pro-inflammatory and an increase in anti-inflammatory molecular pathways. Statin-mediated modulation of molecular intracellular mechanisms in both vascular and immune cells should be considered as a very promising approach to further clarify the statin-induced cardiovascular protection. Beside cardiovascular area, statin therapy is under investigation in other inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis. Many hypotheses have been already proposed to explain statin anti-inflammatory activities. A strong work is waiting for researchers in the next years. 
